While the U.S. has tried to appear assertive in taking action against China’s trade practices, this strategy has yielded limited results. In a new commentary, fellow Simon Lester summarizes current U.S. policies addressing China’s trade conduct and advocates for the U.S.’ revitalized engagement with the World Trade Organization’s dispute settlement system.
The Office of the United States Trade Representative recently stepped back from ongoing negotiations on digital trade at the World Trade Organization, citing unsettled domestic policy, and suspended support for digital trade rules in the Indo-Pacific Economic Framework too. But if the U.S. wants to be a part of the conversation, it should reengage and help craft rules flexible enough to meet its future domestic policy needs, writes nonresident fellow Simon Lester.
Despite recent claims that “free trade is dead,” fellow Simon Lester explains that America was never close to anything resembling free trade in the first place. Instead, current U.S. trade policy, just like past policy, reflects a messy mix of free market and industrial policy views.
Decades of bad policy have heightened the risks of drug use and created barriers to treatment. And while some states are now trying to reduce the harms caused by the drug war, Texas is doubling down on ineffective policies.
The rapid adoption of telemedicine is one of the few positive developments of the COVID-19 pandemic, writes fellow Katharine Neill Harris. She explains why the DEA’s recent proposal to change the rules for prescribing drugs via telemedicine would harm patients and increase demand for and exposure to unregulated and more dangerous drugs.
With the recent enactment of the CHIPS and Science Act, the conversation about industrial policy has started up again. Are state-directed economic policies back, and will such initiatives work?
The death of George Floyd has accelerated calls for police reform. Although decriminalizing drugs and the people who use them will not end police violence, it is part of the structural change needed to fix the problem, writes fellow Katharine Neill Harris.
The collective trauma of the Covid-19 pandemic may provide a clearer understanding of why people use drugs — to help us see it not as a moral failing or a brain malfunction, but as a fundamentally human response to negative life events. Read more at the Baker Institute Blog.